US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Curanex Pharmaceuticals

4.71

-0.5600-10.63%

Post-market: 4.65-0.0600-1.27%19:30 EDT

Volume:28.57K

Turnover:142.78K

Market Cap:7.39M

PE:-0.62

High:5.38

Open:5.10

Low:4.70

Close:5.27

52wk High:183.59

52wk Low:3.58

Shares:1.57M

Float Shares:454.66K

Volume Ratio:0.60

T/O Rate:6.28%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-7.5930

EPS(LYR):-3.3141

ROE:-411.08%

ROA:-225.06%

PB:1.54

PE(LYR):-1.42

Loading ...

Overview Company News Filings

Curanex Pharmaceuticals Inc trading halted, news pending

NASDAQ Trade Halt Halt News Pending at 07:50 Pm

Curanex Net Loss Widens to $3.29 Million in Q2 FY26; no Revenue

Curanex Shareholders Back 1-for-10 to 1-for-50 Reverse Stock Split to Meet NASDAQ $1 Bid Rule

Curanex Pharmaceuticals files draft information statement (Form PRE 14C)

Wisdom Wealth Resources names Hao Xiaohui executive director, co-chairman

Curanex Pharmaceuticals Q1 EPS $(0.11) Down From $(0.01) YoY

Benzinga Earnings

Curanex Pharmaceuticals: Advancing Phyto-N Toward a Planned Investigational New Drug Submission to FDA for Ulcerative Colitis in Q4 2026

THOMSON REUTERS

Curanex Q1 FY26 net loss widens to $3.15 million

Curanex highlights patient case study in treatment of cancer cachexia

Curanex highlights Phyto-N case study supporting potential cancer cachexia supportive-care use

BRIEF-Curanex Pharmaceuticals Expands Drug Development Pipeline

Curanex Pharmaceuticals Inc - to Focus on Cancer Cachexia as New Core Indication - SEC Filing

THOMSON REUTERS

Curanex targets cancer cachexia in pipeline expansion to broaden therapeutics focus

EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases

Benzinga_recent_news

Curanex net loss widens to $4.2 million in FY25

BRIEF-Curanex Pharmaceuticals Inc - Targets Ind Submission For Phyto-N In Q4 2026

Curanex reports no toxicology findings at maximum feasible dose in 28-day Phyto-N study

Curanex Pharmaceuticals Inc - Targets Ind Submission for Phyto-N in Q4 2026

THOMSON REUTERS

Curanex appoints Taku Kambayashi and Selvakumar Subbian to scientific advisory board

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/CURX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CURX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CURX\",,,,,undefined,":{"symbol":"CURX","market":"US","secType":"STK","nameCN":"Curanex Pharmaceuticals","latestPrice":4.71,"timestamp":1787342400000,"preClose":5.27,"halted":0,"volume":28570,"hourTrading":{"tag":"盘后","latestPrice":4.65,"preClose":4.71,"latestTime":"19:30 EDT","volume":1173,"amount":5586.19,"timestamp":1787355008153,"change":-0.06,"changeRate":-0.012739,"amplitude":0.095541},"delay":0,"changeRate":-0.10626185958254263,"floatShares":454655,"shares":1568240,"eps":-7.593,"marketStatus":"Market Closed","change":-0.56,"latestTime":"08-21 16:00:00 EDT","open":5.1,"high":5.38,"low":4.7,"amount":142782.754791,"amplitude":0.129032,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-7.593,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1756180800000,"exchange":"NASDAQ","adjPreClose":5.27,"preHourTrading":{"tag":"盘前","latestPrice":5.08,"preClose":5.27,"latestTime":"09:29 EDT","volume":3002,"amount":14595.757022,"timestamp":1787318999094,"change":-0.19,"changeRate":-0.036053,"amplitude":0.129032},"postHourTrading":{"tag":"盘后","latestPrice":4.65,"preClose":4.71,"latestTime":"19:30 EDT","volume":1173,"amount":5586.19,"timestamp":1787355008153,"change":-0.06,"changeRate":-0.012739,"amplitude":0.095541},"volumeRatio":0.5997715946748173},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CURX\",,,,,undefined,":{"symbol":"CURX","floatShares":454655,"roa":"-225.06%","roe":"-411.08%","lyrEps":-3.31414,"volumeRatio":0.5997715946748173,"shares":1568240,"dividePrice":0,"high":5.38,"amplitude":0.129032,"preClose":5.27,"low":4.7,"week52Low":3.576,"pbRate":"1.54","week52High":183.592,"institutionHeld":0,"latestPrice":4.71,"eps":-7.593,"divideRate":0,"volume":28570,"delay":0,"ttmEps":-7.593,"open":5.1,"prevYearClose":6.612,"prevWeekClose":4.348,"prevMonthClose":4.104,"prevQuarterClose":5.304,"fiveDayClose":4.348,"twentyDayClose":3.758,"sixtyDayClose":6.86},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CURX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-20","symbol":"CURX","defaultRemindTime":1787232600000,"type":"split","dateTimestamp":1787198400000,"forFactor":20,"toFactor":1,"ratio":20}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CURX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CURX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CURX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CURX","date":"2026-08-21","current":-0.620308,"percent":0.987805,"low":-596.14306,"twenty":-39.017362,"median":-7.806171,"eighty":-1.254867,"high":-0.576326,"avg":-38.783436,"sd":105.685071,"marketCap":7474124},"quantilePoints":[{"date":"2025-08-29","current":-343.821021,"twenty":-323.7357,"median":-309.527845,"eighty":-285.033231,"marketCap":144022500},{"date":"2025-09-05","current":-470.352457,"twenty":-397.745937,"median":-357.40162,"eighty":-309.364317,"marketCap":197025000},{"date":"2025-09-12","current":-522.424684,"twenty":-490.623986,"median":-396.156013,"eighty":-317.040593,"marketCap":227272500},{"date":"2025-09-19","current":-81.3514,"twenty":-518.980126,"median":-404.105632,"eighty":-309.03726,"marketCap":35390625},{"date":"2025-09-26","current":-44.190079,"twenty":-502.869283,"median":-357.40162,"eighty":-78.227506,"marketCap":19224187},{"date":"2025-10-03","current":-52.064896,"twenty":-490.623986,"median":-308.710204,"eighty":-52.935681,"marketCap":22650000},{"date":"2025-10-10","current":-48.094947,"twenty":-477.242127,"median":-89.974648,"eighty":-50.763274,"marketCap":20922937},{"date":"2025-10-17","current":-45.236453,"twenty":-457.103092,"median":-68.335176,"eighty":-47.069268,"marketCap":19679395},{"date":"2025-10-24","current":-42.064901,"twenty":-400.925784,"median":-54.241859,"eighty":-44.399354,"marketCap":18299662},{"date":"2025-10-31","current":-42.99649,"twenty":-384.761559,"median":-51.4271,"eighty":-44.033885,"marketCap":18704935},{"date":"2025-11-07","current":-39.915076,"twenty":-365.54998,"median":-50.763274,"eighty":-43.476372,"marketCap":17364415},{"date":"2025-11-14","current":-36.025849,"twenty":-337.125914,"median":-49.550198,"eighty":-42.216596,"marketCap":15672469},{"date":"2025-11-21","current":-9.181804,"twenty":-310.01843,"median":-47.092697,"eighty":-39.195744,"marketCap":11917311},{"date":"2025-11-28","current":-10.640411,"twenty":-308.710204,"median":-46.699426,"eighty":-38.202616,"marketCap":13810477},{"date":"2025-12-05","current":-9.723323,"twenty":-249.517771,"median":-45.236453,"eighty":-36.025849,"marketCap":12620163},{"date":"2025-12-12","current":-10.048671,"twenty":-98.597896,"median":-44.065693,"eighty":-10.640411,"marketCap":13042441},{"date":"2025-12-19","current":-8.629367,"twenty":-81.3514,"median":-43.511146,"eighty":-10.14693,"marketCap":11200288},{"date":"2025-12-26","current":-8.727626,"twenty":-78.227506,"median":-43.029064,"eighty":-9.899316,"marketCap":11327822},{"date":"2026-01-02","current":-7.218797,"twenty":-71.979719,"median":-42.823377,"eighty":-9.635108,"marketCap":9369472},{"date":"2026-01-09","current":-8.085664,"twenty":-66.382742,"median":-40.152859,"eighty":-9.213247,"marketCap":10494602},{"date":"2026-01-16","current":-8.066012,"twenty":-59.883741,"median":-39.074691,"eighty":-8.778721,"marketCap":10469095},{"date":"2026-01-23","current":-7.948101,"twenty":-54.695471,"median":-38.768503,"eighty":-8.563861,"marketCap":10316055},{"date":"2026-01-30","current":-7.314874,"twenty":-52.092225,"median":-38.100754,"eighty":-8.186981,"marketCap":9494172},{"date":"2026-02-06","current":-5.851898,"twenty":-51.809778,"median":-36.025849,"eighty":-8.048981,"marketCap":7595337},{"date":"2026-02-13","current":-6.052785,"twenty":-51.302144,"median":-21.964742,"eighty":-8.00007,"marketCap":7856073},{"date":"2026-02-20","current":-6.982974,"twenty":-51.044424,"median":-10.640411,"eighty":-7.876918,"marketCap":9063391},{"date":"2026-02-27","current":-10.04212,"twenty":-50.763274,"median":-10.175316,"eighty":-7.808791,"marketCap":13033939},{"date":"2026-03-06","current":-8.714526,"twenty":-50.670859,"median":-10.110902,"eighty":-7.819272,"marketCap":11310818},{"date":"2026-03-13","current":-8.402278,"twenty":-50.150997,"median":-10.04212,"eighty":-7.828006,"marketCap":10905544},{"date":"2026-03-20","current":-9.280064,"twenty":-49.259148,"median":-9.875079,"eighty":-7.876918,"marketCap":12044845},{"date":"2026-03-27","current":-11.160095,"twenty":-47.902307,"median":-10.007184,"eighty":-7.935873,"marketCap":14484989},{"date":"2026-04-02","current":-3.420935,"twenty":-47.131746,"median":-10.007184,"eighty":-7.862943,"marketCap":14453814},{"date":"2026-04-10","current":-3.156639,"twenty":-47.053649,"median":-9.875079,"eighty":-7.677342,"marketCap":13337134},{"date":"2026-04-17","current":-2.999546,"twenty":-46.858406,"median":-9.825949,"eighty":-7.314874,"marketCap":12673398},{"date":"2026-04-24","current":-2.974706,"twenty":-46.540445,"median":-9.634889,"eighty":-7.070316,"marketCap":12568448},{"date":"2026-05-01","current":-2.799486,"twenty":-45.452654,"median":-9.498418,"eighty":-6.683829,"marketCap":11828126},{"date":"2026-05-08","current":-2.118748,"twenty":-45.236453,"median":-9.257136,"eighty":-6.550633,"marketCap":8951934},{"date":"2026-05-15","current":-2.100622,"twenty":-44.190079,"median":-9.17307,"eighty":-6.181613,"marketCap":8875349},{"date":"2026-05-22","current":-1.285435,"twenty":-44.13655,"median":-8.952531,"eighty":-5.851898,"marketCap":9303658},{"date":"2026-05-29","current":-1.343828,"twenty":-44.02318,"median":-8.880475,"eighty":-3.394795,"marketCap":9726294},{"date":"2026-06-05","current":-1.301111,"twenty":-43.831987,"median":-8.727626,"eighty":-3.148449,"marketCap":9417117},{"date":"2026-06-12","current":-1.320706,"twenty":-43.567172,"median":-8.671947,"eighty":-3.065336,"marketCap":9558941},{"date":"2026-06-18","current":-1.312868,"twenty":-43.485065,"median":-8.518006,"eighty":-2.978331,"marketCap":9502212},{"date":"2026-06-26","current":-1.022861,"twenty":-43.20451,"median":-8.38481,"eighty":-2.886089,"marketCap":7403215},{"date":"2026-07-02","current":-1.074592,"twenty":-43.016034,"median":-8.299652,"eighty":-2.787402,"marketCap":7777631},{"date":"2026-07-10","current":-0.83083,"twenty":-42.927245,"median":-8.1872,"eighty":-2.394668,"marketCap":6013340},{"date":"2026-07-17","current":-0.855128,"twenty":-42.519987,"median":-8.066012,"eighty":-2.13862,"marketCap":6189201},{"date":"2026-07-24","current":-0.783802,"twenty":-41.395198,"median":-8.034351,"eighty":-1.343985,"marketCap":5672962},{"date":"2026-07-31","current":-0.748531,"twenty":-40.29553,"median":-8.010332,"eighty":-1.321098,"marketCap":5417679},{"date":"2026-08-07","current":-0.763815,"twenty":-39.868052,"median":-7.948101,"eighty":-1.301503,"marketCap":5528301},{"date":"2026-08-14","current":-0.85983,"twenty":-39.558905,"median":-7.841107,"eighty":-1.285827,"marketCap":6223239},{"date":"2026-08-21","current":-0.713972,"twenty":-39.017362,"median":-7.806171,"eighty":-1.254867,"marketCap":7474124}],"updateTime":1787410639926},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CURX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660471835","title":"Curanex Pharmaceuticals Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2660471835","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660471835?lang=en_us&edition=fundamental","pubTime":"2026-08-20 07:50","pubTimestamp":1787183410,"startTime":"0","endTime":"0","summary":"19:50 EDT Curanex (CURX) Pharmaceuticals Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-mov...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/curanex-pharmaceuticals-inc-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/curanex-pharmaceuticals-inc-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CURX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660847974","title":"NASDAQ Trade Halt Halt News Pending at 07:50 Pm","url":"https://stock-news.laohu8.com/highlight/detail?id=2660847974","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660847974?lang=en_us&edition=fundamental","pubTime":"2026-08-20 07:50","pubTimestamp":1787183400,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTHALT NEWS PENDING AT 07:50 PM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nAQN2MFP9Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CURX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659128040","title":"Curanex Net Loss Widens to $3.29 Million in Q2 FY26; no Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2659128040","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659128040?lang=en_us&edition=fundamental","pubTime":"2026-08-15 00:16","pubTimestamp":1786724199,"startTime":"0","endTime":"0","summary":"Curanex net loss widens to $3.29 million in Q2 FY26; no revenueCuranex posted a net loss of $3.29 million for the quarter ended June 30, 2026, versus a $60,346 loss a year earlier.No revenue was repor","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDLccq9LM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CURX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647370880","title":"Curanex Shareholders Back 1-for-10 to 1-for-50 Reverse Stock Split to Meet NASDAQ $1 Bid Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2647370880","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647370880?lang=en_us&edition=fundamental","pubTime":"2026-06-29 22:20","pubTimestamp":1782742806,"startTime":"0","endTime":"0","summary":"Curanex shareholders back 1-for-10 to 1-for-50 reverse stock split to meet Nasdaq $1 bid ruleCuranex Pharmaceuticals’ board adopted resolutions on May 31, 2026, later authorized by majority written co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL8wd4Kj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CURX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644039071","title":"Curanex Pharmaceuticals files draft information statement (Form PRE 14C)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644039071","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644039071?lang=en_us&edition=fundamental","pubTime":"2026-06-19 05:12","pubTimestamp":1781817177,"startTime":"0","endTime":"0","summary":"Curanex shareholders authorized a reverse stock split of common stock, with the ratio set within a 1-for-10 to 1-for-50 range.The board would select the final split ratio, with the move aimed at lifting the per-share trading price.Shareholders also authorized a 2026 equity incentive plan reserving up to 5,700,000 common shares for awards to employees, directors, consultants.The plan includes an annual share reserve increase of up to 4% of outstanding shares, subject to administrator discretion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curanex Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL2yBSHS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CURX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644674835","title":"Wisdom Wealth Resources names Hao Xiaohui executive director, co-chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2644674835","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644674835?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:47","pubTimestamp":1781693239,"startTime":"0","endTime":"0","summary":"Wisdom Wealth Resources Investment Holding Group named Hao Xiaohui executive director, co-chairman effective June 17, 2026.Hao was appointed general manager overseeing financial business on May 28, 2026; also serves as an independent director at Nasdaq-listed Curanex Pharmaceuticals.He previously held senior roles at Bank of Communications, including New York branch general manager, Hong Kong branch deputy CEO.Xu Shiping shifted from chairman to co-chairman; remains executive director, nomination committee chair.Shares have been suspended from trading since April 2, 2024.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wisdom Wealth Resources Investment Holding Group Limited published the original content used to generate this news brie","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDLb8h9W1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","601328","00007","BK0278","BK0183","BK1124","BK0020","BK0015","BK0187","BK0188","CURX","BK0012","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635710711","title":"Curanex Pharmaceuticals Q1 EPS $(0.11) Down From $(0.01) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2635710711","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635710711?lang=en_us&edition=fundamental","pubTime":"2026-05-14 21:05","pubTimestamp":1778763955,"startTime":"0","endTime":"0","summary":"Curanex Pharmaceuticals (NASDAQ:CURX) reported quarterly losses of $(0.11) per share. This is a 1000 percent decrease over losses of $(0.01) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52558969/curanex-pharmaceuticals-q1-eps-0-11-down-from-0-01-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CURX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635771058","title":"Curanex Pharmaceuticals: Advancing Phyto-N Toward a Planned Investigational New Drug Submission to FDA for Ulcerative Colitis in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635771058","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635771058?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:53","pubTimestamp":1778763219,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nFWN41R13R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CURX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635108967","title":"Curanex Q1 FY26 net loss widens to $3.15 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635108967","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635108967?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:48","pubTimestamp":1778762920,"startTime":"0","endTime":"0","summary":"Curanex posted a net loss of USD 3.15 million for Q1 ended March 31, 2026, widening from a loss of USD 137,583 a year earlier, while reporting no revenue.General and administrative expense climbed to USD 927,197 from USD 137,452, driven by higher personnel-related costs and higher public-company professional fees.Research and development expense rose to USD 2.26 million as it continued IND-related studies, with prepaid R&D at USD 3.9 million for advance payments to CROs and CDMOs.Cash and cash equivalents totaled USD 4.02 million at March 31, 2026, versus USD 198,943 a year earlier, following about USD 15.3 million in net IPO proceeds received in 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curanex Pharmaceuticals Inc. publishe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL6lXTcR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CURX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625672691","title":"Curanex highlights patient case study in treatment of cancer cachexia","url":"https://stock-news.laohu8.com/highlight/detail?id=2625672691","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625672691?lang=en_us&edition=fundamental","pubTime":"2026-04-06 21:58","pubTimestamp":1775483905,"startTime":"0","endTime":"0","summary":"Curanex (CURX) highlighted a patient case study that management believes further supports the company’s strategic interest in treatment of cancer c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/curanex-highlights-patient-case-study-in-treatment-of-cancer-cachexia-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/curanex-highlights-patient-case-study-in-treatment-of-cancer-cachexia-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CURX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625745026","title":"Curanex highlights Phyto-N case study supporting potential cancer cachexia supportive-care use","url":"https://stock-news.laohu8.com/highlight/detail?id=2625745026","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625745026?lang=en_us&edition=fundamental","pubTime":"2026-04-06 21:17","pubTimestamp":1775481438,"startTime":"0","endTime":"0","summary":"Curanex highlighted patient case study supporting potential of lead program Phyto-N in cancer cachexia, with results already presented in company materials.Case narrative described improved quality of life and functional status, with patient able to maintain daily activities for more than two years before surgery.Company positioned cachexia as major unmet need in supportive oncology, with strategic development focus expanded to evaluate Phyto-N in that setting.Phyto-N remains in preclinical work for ulcerative colitis, with planned IND submission still ahead.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL9RLk7X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BN0W2V16.EUR","SG9999014013.SGD","LU2095319765.USD","BK4585","SG9999014021.USD","LU0314104364.USD","BK4112","SG9999014005.SGD","LU2210150020.SGD","SG9999014039.USD","BK4007","IE00BN0W2W23.USD","NDAQ","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BN0W2T93.GBP","CURX","BK4588","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624502516","title":"BRIEF-Curanex Pharmaceuticals Expands Drug Development Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2624502516","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624502516?lang=en_us&edition=fundamental","pubTime":"2026-04-02 21:49","pubTimestamp":1775137796,"startTime":"0","endTime":"0","summary":"BRIEF-Curanex Pharmaceuticals Expands Drug Development Pipeline April 2  - Curanex Pharmaceuticals Inc CURX.O:CURANEX PHARMACEUTICALS INC - EXPANDS DRUG DEVELOPMENT PIPELINE - SEC FILINGCURANEX PHARMACEUTICALS INC - TO FOCUS ON CANCER CACHEXIA AS NEW CORE INDICATION - SEC FILINGSource text: [ID:n0001493152-26-014815]Further company coverage: CURX.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nFWN40L0UX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CURX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624509316","title":"Curanex Pharmaceuticals Inc - to Focus on Cancer Cachexia as New Core Indication - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624509316","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624509316?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:22","pubTimestamp":1775132532,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nFWN40L0UX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CURX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624064915","title":"Curanex targets cancer cachexia in pipeline expansion to broaden therapeutics focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2624064915","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624064915?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:08","pubTimestamp":1775131687,"startTime":"0","endTime":"0","summary":"Curanex broadened pipeline strategy to add cancer cachexia as a new core indication, expanding beyond its existing focus areas.Company plans to pursue drug development in cancer cachexia, targeting an area with no approved therapies in US.Curanex expects cancer cachexia to be a long-term commercial growth driver, with global market estimated at USD 2.54 billion in 2024.Lead program Phyto-N remains on track for a planned IND filing in ulcerative colitis while management evaluates additional development opportunities tied to inflammation and metabolic dysfunction.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDLVHGWK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BK4112","SG9999014039.USD","IE00BN0W2V16.EUR","BK4007","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014005.SGD","LU2095319765.USD","SG9999014013.SGD","LU2210150020.SGD","SG9999014021.USD","IE00BKPKM429.USD","LU0314104364.USD","IE00BGHQF748.EUR","CURX","NDAQ","BK4585","BK4588","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624506628","title":"EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2624506628","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624506628?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:53","pubTimestamp":1775130780,"startTime":"0","endTime":"0","summary":"Curanex expands pipeline with cancer cachexia, advances Phyto-N toward IND, and reports preclinical safety data.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/02/Cancer---Heart-Shape-To-Represent-Medica.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/02/Cancer---Heart-Shape-To-Represent-Medica.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/biotech/26/04/51621768/exclusive-curanex-pipeline-expansion-signals-push-beyond-inflammation-metabolic-diseases","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/biotech/26/04/51621768/exclusive-curanex-pipeline-expansion-signals-push-beyond-inflammation-metabolic-diseases","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["IND","BK4007","CURX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623242543","title":"Curanex net loss widens to $4.2 million in FY25","url":"https://stock-news.laohu8.com/highlight/detail?id=2623242543","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623242543?lang=en_us&edition=fundamental","pubTime":"2026-03-31 05:50","pubTimestamp":1774907438,"startTime":"0","endTime":"0","summary":"Curanex posted a net loss of $4.2 million for fiscal 2025, widening from a $361,506 loss a year earlier.Revenue was unchanged with no revenue in 2025.Research and development expense climbed to $3 million, driven by expanded IND-enabling studies across multiple indications.Cash and cash equivalents rose to $5 million at year-end following net IPO proceeds of about $15.3 million.Curanex plans to submit an IND for ulcerative colitis in 4Q 2026, with a Phase I trial slated to start 30 days after submission if cleared by FDA.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curanex Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system oper","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL70vfZW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CURX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620535922","title":"BRIEF-Curanex Pharmaceuticals Inc - Targets Ind Submission For Phyto-N In Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620535922","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620535922?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:05","pubTimestamp":1773835523,"startTime":"0","endTime":"0","summary":"BRIEF-Curanex Pharmaceuticals Inc - Targets Ind Submission For Phyto-N In Q4 2026March 18 (Reuters) - Curanex Pharmaceuticals Inc CURX.O:CURANEX PHARMACEUTICALS INC - TARGETS IND SUBMISSION FOR PHYTO-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN40615R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CURX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620253597","title":"Curanex reports no toxicology findings at maximum feasible dose in 28-day Phyto-N study","url":"https://stock-news.laohu8.com/highlight/detail?id=2620253597","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620253597?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:05","pubTimestamp":1773835505,"startTime":"0","endTime":"0","summary":"Curanex reported completion of a 28-day repeat-dose oral dose-range finding toxicology study of Phyto-N in Sprague-Dawley rats and dogs. The maximum feasible dose was approximately 6x the proposed clinical oral dose in dogs and approximately 4x in rats. Across hematology, coagulation, serum biochemistry, and organ pathology assessments, the company reported no treatment-related adverse findings of toxicological significance at any dose level in either species. Curanex said the results will be used to inform dose selection and design for planned GLP-compliant toxicology studies supporting a targeted IND submission in Q4 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLbJkGM6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BN0W2V16.EUR","SG9999014013.SGD","LU2095319765.USD","BK4585","SG9999014021.USD","LU0314104364.USD","BK4112","SG9999014005.SGD","LU2210150020.SGD","SG9999014039.USD","BK4007","IE00BN0W2W23.USD","NDAQ","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BN0W2T93.GBP","CURX","BK4588","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620253559","title":"Curanex Pharmaceuticals Inc - Targets Ind Submission for Phyto-N in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620253559","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620253559?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:04","pubTimestamp":1773835492,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN40615R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CURX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618137729","title":"Curanex appoints Taku Kambayashi and Selvakumar Subbian to scientific advisory board","url":"https://stock-news.laohu8.com/highlight/detail?id=2618137729","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618137729?lang=en_us&edition=fundamental","pubTime":"2026-03-12 21:30","pubTimestamp":1773322214,"startTime":"0","endTime":"0","summary":"Curanex appointed Taku Kambayashi and Selvakumar Subbian to its Scientific Advisory Board. Taku Kambayashi is a Professor of Pathology and Laboratory Medicine at the University of Pennsylvania’s Perelman School of Medicine and serves as Chair of the Immunology Graduate Group at Penn. Selvakumar Subbian is a Professor in the Department of Medicine and a Principal Investigator at the Public Health Research Institute, New Jersey Medical School, Rutgers University. Curanex said it plans to disclose one additional accepted Scientific Advisory Board member after the advisor’s current employer approves a draft press release.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL7mnWt5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","BK4585","SG9999014039.USD","SG9999014005.SGD","LU2095319765.USD","RCH.UK","BK4588","IE00B3QW5Z07.USD","NDAQ","LU2210150020.SGD","BK5004","CURX","LU2210149790.SGD","LU0314104364.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4007","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":31,"code":"91000000","status":"200"}]}}